Vaccine Sales Market Report 2023-2033

The overall world revenue for Vaccine Sales Market, 2023 to 2033 in terms of value will surpass US$120 billion in 2023. The author predicts strong revenue growth through to 2033. This work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Vaccine Sales Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Investment in the Development of Vaccines to Boost Industry Growth

The growing attention towards vaccine research is attributed to the significant advancements in the domains of microbial pathogenesis and immunology. These developments have facilitated researchers and developers in devising preventive and therapeutic vaccines, as well as targeting novel diseases that were previously deemed unfeasible. Apart from the scientific progress, the current expansion of the worldwide vaccine market and the potential to attain "blockbuster" status by generating substantial sales revenue have motivated vaccine producers to revitalise and/or broaden their research endeavours. This is aimed at enhancing the public health impact while also achieving commercial success.

What Questions Should You Ask before Buying a Market Research Report?

How is the vaccine sales market evolving?
What is driving and restraining the vaccine sales market?
How will each vaccine sales submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
How will the market shares for each vaccine sales submarket develop from 2023 to 2033?
What will be the main driver for the overall market from 2023 to 2033?
Will leading vaccine sales markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
Who are the leading players and what are their prospects over the forecast period?
What are the vaccine sales projects for these leading companies?
How will the industry evolve during the period between 2023 and 2033? What are the implications of

vaccine sales projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the vaccine sales market?
Where is the vaccine sales market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the vaccine sales market today, and over the next 10 years:

The 364-page report provides 140 tables and 199 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the vaccine sales market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2033, this new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type

Inactivated
Live Attenuated
Toxoid
Recombinant/Conjugate/Subunit

Application

Pneumococcal
Influenza
Hepatitis
Meningococcal
COVID-19
Others

Route of Administration

Intramuscular
Subcutaneous
Oral

Distribution Channel

Hospital & Retail Pharmacies
Government Suppliers
Others

Age Group

Paediatrics
Adults

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
South-East Asia
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles and for some of the leading companies in the Vaccine Sales Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL
Daiichi Sankyo, Inc.
Emergent BioSolutions Inc.
GSK plc
INOVIO Pharmaceuticals
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Moderna, Inc.
Novavax
Panacea Biotec
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
Sinopharm
SINOVAC
Takeda Pharmaceutical Company Limited

How will the Vaccine Sales Market, 2023 to 2033 report help you?

In summary, this 360+ page report provides you with the following knowledge:

Revenue forecasts to 2033 for Vaccine Sales Market, 2023 to 2033 Market, with forecasts for type, application, route of administration, distribution channel, and age group, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2033 for five regional and 22 key national markets - See forecasts for the Vaccine Sales Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Vaccine Sales Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how the work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Vaccine Sales Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Vaccine Sales Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rising Focus and Government Support on Immunization Programs
3.2.1.2 Growing Investment in Vaccine Development
3.2.1.3 Increasing Company Initiatives to Enhance Vaccine R&D
3.2.1.4 High Prevalence of Infectious Diseases
3.2.1.5 Technological Advancements in Vaccine Administration
3.2.1.6 Rapid Need of Immunization
3.2.1.7 Strong Supply Backed Up by Robust R&D to Drive the Market
3.2.2 Market Restraining Factors
3.2.2.1 Inadequate Reimbursement Coverage
3.2.2.2 High Cost of Vaccine Development
3.2.2.3 Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
3.2.2.4 Stringent Government Regulations for Approval
3.2.2.5 Inadequate Access to Vaccines
3.2.2.6 Product Recalls
3.2.3 Market Opportunities
3.2.3.1 High Growth Prospects in Emerging Markets
3.2.3.2 Focus on Therapeutic Vaccines
3.2.3.3 Use of Adjuvants in Vaccines
3.2.3.4 Government Support for Future Vaccine R&D
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Supplier
3.4.2 Bargaining Power of Buyer
3.4.3 Competitive Rivalry
3.4.4 Threat of New Entrants
3.4.5 Threat of Substitutes
3.5 PEST Analysis

4 Vaccine Sales Market Analysis by Type

4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Vaccine Sales Market Size Estimation and Forecast by Type
4.4 Inactivated
4.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Live Attenuated
4.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Toxoid
4.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Recombinant/Conjugate/Subunit
4.7.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
4.7.2 Market Share by Region, 2023 & 2033 (%)

5 Vaccine Sales Market Analysis by Application

5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Vaccine Sales Market Size Estimation and Forecast by Application
5.4 Pneumococcal
5.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Influenza
5.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Hepatitis
5.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Meningococcal
5.7.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 COVID-19
5.8.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Others
5.9.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
5.9.2 Market Share by Region, 2023 & 2033 (%)

6 Vaccine Sales Market Analysis by Route of Administration

6.1 Key Findings
6.2 Route of Administration Segment: Market Attractiveness Index
6.3 Vaccine Sales Market Size Estimation and Forecast by Route of Administration
6.4 Intramuscular
6.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Subcutaneous
6.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Oral
6.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Vaccine Sales Market Analysis by Distribution Channel

7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital & Retail Pharmacies
7.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 Government Suppliers
7.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Others
7.6.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
7.6.2 Market Share by Region, 2023 & 2033 (%)

8 Vaccine Sales Market Analysis by Age Group

8.1 Key Findings
8.2 Age Group Segment: Market Attractiveness Index
8.3 Vaccine Sales Market Size Estimation and Forecast by Age Group
8.4 Paediatrics
8.4.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
8.4.2 Market Share by Region, 2023 & 2033 (%)
8.5 Adults
8.5.1 Market Forecast by Region, 2023-2033 (US$ Bn, AGR %)
8.5.2 Market Share by Region, 2023 & 2033 (%)

9 Vaccine Sales Market Analysis by Region

9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Vaccine Sales Market Analysis

10.1 Key Findings
10.2 North America Vaccine Sales Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
10.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
10.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
10.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
10.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
10.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
10.10 U.S. Vaccine Sales Market Analysis
10.11 Canada Vaccine Sales Market Analysis

11 Europe Vaccine Sales Market Analysis

11.1 Key Findings
11.2 Europe Vaccine Sales Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
11.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
11.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
11.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
11.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
11.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
11.10 Germany Vaccine Sales Market Analysis
11.11 UK Vaccine Sales Market Analysis
11.12 France Vaccine Sales Market Analysis
11.13 Italy Vaccine Sales Market Analysis
11.14 Spain Vaccine Sales Market Analysis
11.15 Russia Vaccine Sales Market Analysis
11.16 Rest of Europe Vaccine Sales Market Analysis

12 Asia Pacific Vaccine Sales Market Analysis

12.1 Key Findings
12.2 Asia Pacific Vaccine Sales Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
12.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
12.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
12.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
12.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
12.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
12.10 Japan Vaccine Sales Market Analysis
12.11 China Vaccine Sales Market Analysis
12.12 India Vaccine Sales Market Analysis
12.13 Australia Vaccine Sales Market Analysis
12.14 South Korea Vaccine Sales Market Analysis
12.15 South-East Asia Vaccine Sales Market Analysis
12.16 Rest of Asia Pacific Vaccine Sales Market Analysis

13 Latin America Vaccine Sales Market Analysis

13.1 Key Findings
13.2 Latin America Vaccine Sales Market Attractiveness Index
13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
13.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
13.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
13.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
13.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
13.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
13.10 Brazil Vaccine Sales Market Analysis
13.11 Mexico Vaccine Sales Market Analysis
13.12 Rest of Latin America Vaccine Sales Market Analysis

14 MEA Vaccine Sales Market Analysis

14.1 Key Findings
14.2 MEA Vaccine Sales Market Attractiveness Index
14.3 Market Size by Country, 2023, 2028 & 2033 (US$ Bn)
14.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Bn)
14.5 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Bn)
14.6 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Bn)
14.7 Market Size Estimation and Forecast by Route of Administration, 2023-2033 (US$ Bn)
14.8 Market Size Estimation and Forecast by Distribution Channel, 2023-2033 (US$ Bn)
14.9 Market Size Estimation and Forecast by Age Group, 2023-2033 (US$ Bn)
14.10 GCC Vaccine Sales Market Analysis
14.11 South Africa Vaccine Sales Market Analysis
14.12 Rest of MEA Vaccine Sales Market Analysis

15 Company Profiles

15.1 Bavarian Nordic
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2015-2022
15.1.3.2 R&D, 2015-2022
15.1.3.3 Regional Market Shares, 2022
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bharat Biotech
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.2.4 Strategic Outlook
15.3 CSL
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2015-2022
15.3.3.2 R&D, 2015-2022
15.3.3.3 Regional Market Shares, 2022
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Emergent BioSolutions Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2015-2022
15.4.3.2 R&D, 2015-2022
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 GSK plc
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2015-2022
15.5.3.2 R&D, 2015-2022
15.5.3.3 Regional Market Shares, 2022
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 INOVIO Pharmaceuticals
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2015-2022
15.6.3.2 R&D, 2015-2022
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Johnson & Johnson Services, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2015-2022
15.7.3.2 R&D, 2015-2022
15.7.3.3 Regional Market Shares, 2022
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 Merck Co., Inc.
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2015-2022
15.8.3.2 R&D, 2015-2022
15.8.3.3 Regional Market Shares, 2022
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Mitsubishi Tanabe Pharma Corporation
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Strategic Outlook
15.10 Moderna, Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2015-2022
15.10.3.2 R&D, 2015-2022
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Novavax
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2015-2022
15.11.3.2 R&D, 2015-2022
15.11.3.3 Regional Market Shares, 2022
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Panacea Biotec
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Product Benchmarking
15.13 Pfizer Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2015-2022
15.13.3.2 R&D, 2015-2022
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Sanofi
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Financial Analysis
15.14.3.1 Net Revenue, 2015-2022
15.14.3.2 R&D, 2015-2022
15.14.3.3 Regional Market Shares, 2022
15.14.4 Product Benchmarking
15.14.5 Strategic Outlook
15.15 Serum Institute of India Pvt. Ltd.
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Product Benchmarking
15.15.4 Strategic Outlook
15.16 AstraZeneca
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Financial Analysis
15.16.3.1 Net Revenue, 2015-2022
15.16.3.2 R&D, 2015-2022
15.16.3.3 Regional Market Shares, 2022
15.16.4 Product Benchmarking
15.16.5 Strategic Outlook
15.17 Sinopharm
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Product Benchmarking
15.18 SINOVAC
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2015-2022
15.18.3.2 R&D, 2015-2022
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook
15.19 Takeda Pharmaceutical Company Limited
15.19.1 Company Snapshot
15.19.2 Company Overview
15.19.3 Financial Analysis
15.19.3.1 Net Revenue, 2015-2022
15.19.3.2 R&D, 2015-2022
15.19.3.3 Regional Market Shares, 2022
15.19.4 Product Benchmarking
15.19.5 Strategic Outlook
15.20 Daiichi Sankyo, Inc.
15.20.1 Company Snapshot
15.20.2 Company Overview
15.20.3 Financial Analysis
15.20.3.1 Net Revenue, 2015-2022
15.20.3.2 R&D, 2015-2022
15.20.4 Product Benchmarking
15.20.5 Strategic Outlook

16 Conclusion and Recommendations

16.1 Concluding Remarks from
16.2 Recommendations for Market Players

List of Tables

Table 1 Vaccine Sales Market Snapshot, 2023 & 2033 (US$ Billion, CAGR %)
Table 2 Vaccine Cost Comparison: CDC Cost vs. Private Sector Cost (US$)
Table 3 Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): V Shaped Recovery
Table 4 Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): U Shaped Recovery
Table 5 Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): W Shaped Recovery
Table 6 Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%): L Shaped Recovery
Table 7 Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 8 Inactivated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 9 Live Attenuated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 10 Toxoid Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 11 Recombinant/Conjugate/Subunit Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 12 Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 13 Pneumococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 14 Influenza Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 15 Hepatitis Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 16 Meningococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 17 COVID-19 Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 18 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 19 Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 20 Intramuscular Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 21 Subcutaneous Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 22 Oral Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 23 Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 24 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 25 Government Suppliers Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 26 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 27 Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 28 Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 29 Adults Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 30 Vaccine Sales Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 31 North America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 32 North America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 33 North America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 34 North America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 35 North America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 36 North America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 37 U.S. Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 38 Canada Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 39 Europe Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 40 Europe Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 41 Europe Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 42 Europe Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 43 Europe Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 44 Europe Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 45 Germany Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 46 UK Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 47 France Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 48 Italy Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 49 Spain Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 50 Russia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 51 Rest of Europe Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 52 Asia Pacific Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 53 Asia Pacific Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 54 Asia Pacific Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 56 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 57 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 58 Japan Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 59 China Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 60 India Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 61 Australia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 62 South Korea Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 63 South-East Asia Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 65 Latin America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 70 Latin America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 71 Brazil Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 72 Mexico Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 73 Rest of Latin America Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 74 MEA Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 75 MEA Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 76 MEA Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 78 MEA Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 79 MEA Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 80 GCC Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 81 South Africa Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 82 Rest of MEA Vaccine Sales Market Forecast, 2023-2033 (US$ Bn, AGR%, CAGR%)
Table 83 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Bavarian Nordic: Product Benchmarking
Table 85 Bavarian Nordic: Strategic Outlook
Table 86 Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Bharat Biotech: Product Benchmarking
Table 88 Bharat Biotech: Strategic Outlook
Table 89 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 CSL: Product Benchmarking
Table 91 CSL: Strategic Outlook
Table 92 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Emergent BioSolutions Inc.: Product Benchmarking
Table 94 Emergent BioSolutions Inc.: Strategic Outlook
Table 95 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 GSK plc: Product Benchmarking
Table 97 GSK plc: Strategic Outlook
Table 98 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 INOVIO Pharmaceuticals: Product Benchmarking
Table 100 INOVIO Pharmaceuticals: Strategic Outlook
Table 101 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 103 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 104 Merck Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Merck Co., Inc.: Product Benchmarking
Table 106 Merck Co., Inc.: Strategic Outlook
Table 107 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 109 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 110 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Moderna, Inc.: Product Benchmarking
Table 112 Moderna, Inc.: Strategic Outlook
Table 113 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Novavax: Product Benchmarking
Table 115 Novavax: Strategic Outlook
Table 116 Panacea Biotec.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Panacea Biotec: Product Benchmarking
Table 118 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Pfizer Inc.: Product Benchmarking
Table 120 Pfizer Inc.: Strategic Outlook
Table 121 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Sanofi: Product Benchmarking
Table 123 Sanofi: Strategic Outlook
Table 124 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 126 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 127 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 AstraZeneca: Product Benchmarking
Table 129 AstraZeneca: Strategic Outlook
Table 130 Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Sinopharm: Product Benchmarking
Table 132 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 SINOVAC: Product Benchmarking
Table 134 SINOVAC: Strategic Outlook
Table 135 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 137 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 138 Daiichi Sankyo, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Daiichi Sankyo, Inc.: Product Benchmarking
Table 140 Daiichi Sankyo, Inc.: Strategic Outlook

List of Figures

Figure 1 Vaccine Sales Market Segmentation
Figure 2 Vaccine Sales Market by Type: Market Attractiveness Index
Figure 3 Vaccine Sales Market by Application: Market Attractiveness Index
Figure 4 Vaccine Sales Market by Route of Administration: Market Attractiveness Index
Figure 5 Vaccines market by distribution channel: Market Attractiveness Index
Figure 6 Vaccine Sales Market by Age Group: Market Attractiveness Index
Figure 7 Vaccine Sales Market Attractiveness Index by Region
Figure 8 Vaccine Sales Market: Market Dynamics
Figure 9 Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): “V” Shaped Recovery
Figure 10 Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): “U” Shaped Recovery
Figure 11 Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): “W” Shaped Recovery
Figure 12 Vaccine Sales Market by Region, 2023-2033 (US$ Bn, AGR %): “L” Shaped Recovery
Figure 13 Vaccine Sales Market: Porter’s Five Forces Analysis
Figure 14 Vaccine Sales Market: PEST Analysis
Figure 15 Vaccine Sales Market Attractiveness Index by Type
Figure 16 Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 17 Vaccine Sales Market Share Forecast by Type, 2023, 2028, 2033 (%)
Figure 18 Inactivated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 19 Inactivated Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Live Attenuated Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 21 Live Attenuated Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Toxoid Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 23 Toxoid Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Recombinant/Conjugate/Subunit Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 25 Recombinant/Conjugate/Subunit Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Vaccine Sales Market Attractiveness Index by Type
Figure 27 Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 28 Vaccine Sales Market Share Forecast by Application, 2023, 2028, 2033 (%)
Figure 29 Pneumococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 30 Pneumococcal Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 Influenza Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 32 Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Hepatitis Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 34 Hepatitis Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 35 Meningococcal Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 36 Meningococcal Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 37 COVID-19 Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 38 COVID-19 Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 39 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 40 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Vaccine Sales Market Attractiveness Index by Route of Administration
Figure 42 Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 43 Vaccine Sales Market Share Forecast by Route of Administration, 2023, 2028, 2033 (%)
Figure 44 Intramuscular Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 45 Intramuscular Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 46 Subcutaneous Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 47 Subcutaneous Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Oral Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 49 Oral Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Vaccine Sales Market Attractiveness Index by Distribution Channel
Figure 51 Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 52 Vaccine Sales Market Share Forecast by Distribution Channel, 2023, 2028, 2033 (%)
Figure 53 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 54 Hospital & Retail Pharmacies Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 55 Government Suppliers Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 56 Government Suppliers Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 57 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 58 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 59 Vaccine Sales Market Attractiveness Index by Age Group
Figure 60 Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 61 Vaccine Sales Market Share Forecast by Age Group, 2023, 2028, 2033 (%)
Figure 62 Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 63 Paediatrics Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 64 Adults Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR %)
Figure 65 Adults Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 66 Vaccine Sales Market Forecast by Region 2023 & 2033 (Revenue, CAGR%)
Figure 67 Vaccine Sales Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 68 Vaccine Sales Market by Region, 2023-2033 (US$ Bn)
Figure 69 North America Vaccine Sales Market Attractiveness Index
Figure 70 North America Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 71 North America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 72 North America Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
Figure 73 North America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 74 North America Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
Figure 75 North America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 76 North America Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
Figure 77 North America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 78 North America Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 79 North America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 80 North America Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 81 North America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 82 North America Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
Figure 83 U.S. Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 84 Canada Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 85 Europe Vaccine Sales Market Attractiveness Index
Figure 86 Europe Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 87 Europe Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 88 Europe Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
Figure 89 Europe Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 90 Europe Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
Figure 91 Europe Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 92 Europe Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
Figure 93 Europe Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 94 Europe Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 95 Europe Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 96 Europe Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 97 Europe Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 98 Europe Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
Figure 99 Germany Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 100 UK Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 101 France Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 102 Italy Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 103 Spain Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 104 Russia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 105 Rest of Europe Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 106 Asia Pacific Vaccine Sales Market Attractiveness Index
Figure 107 Asia Pacific Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 108 Asia Pacific Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 109 Asia Pacific Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
Figure 110 Asia Pacific Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 111 Asia Pacific Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
Figure 112 Asia Pacific Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 113 Asia Pacific Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
Figure 114 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 115 Asia Pacific Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 116 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 117 Asia Pacific Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 118 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 119 Asia Pacific Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
Figure 120 Japan Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 121 China Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 122 India Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 123 Australia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 124 South Korea Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 125 South-East Asia Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 126 Rest of Asia Pacific Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 127 Latin America Vaccine Sales Market Attractiveness Index
Figure 128 Latin America Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 129 Latin America Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 130 Latin America Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
Figure 131 Latin America Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 132 Latin America Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
Figure 133 Latin America Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 134 Latin America Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
Figure 135 Latin America Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 136 Latin America Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 137 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 138 Latin America Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 139 Latin America Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 140 Latin America Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
Figure 141 Brazil Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 142 Mexico Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 143 Rest of Latin America Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 144 MEA Vaccine Sales Market Attractiveness Index
Figure 145 MEA Vaccine Sales Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 146 MEA Vaccine Sales Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 147 MEA Vaccine Sales Market Share Forecast by Country, 2023 & 2033 (%)
Figure 148 MEA Vaccine Sales Market Forecast by Type, 2023-2033 (US$ Billion, AGR %)
Figure 149 MEA Vaccine Sales Market Share Forecast by Type, 2023 & 2033 (%)
Figure 150 MEA Vaccine Sales Market Forecast by Application, 2023-2033 (US$ Billion, AGR %)
Figure 151 MEA Vaccine Sales Market Share Forecast by Application, 2023 & 2033 (%)
Figure 152 MEA Vaccine Sales Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR %)
Figure 153 MEA Vaccine Sales Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 154 MEA Vaccine Sales Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR %)
Figure 155 MEA Vaccine Sales Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 156 MEA Vaccine Sales Market Forecast by Age Group, 2023-2033 (US$ Billion, AGR %)
Figure 157 MEA Vaccine Sales Market Share Forecast by Age Group, 2023 & 2033 (%)
Figure 158 GCC Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 159 South Africa Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 160 Rest of MEA Vaccine Sales Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 161 Bavarian Nordic: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 162 Bavarian Nordic: R&D, 2015-2022 (US$ Million, AGR %)
Figure 163 Bavarian Nordic: Regional Market Shares, 2022
Figure 164 CSL: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 165 CSL: R&D, 2015-2022 (US$ Million, AGR %)
Figure 166 CSL: Regional Market Shares, 2022
Figure 167 Emergent BioSolutions Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 168 Emergent BioSolutions Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 169 GSK plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 170 GSK plc: R&D, 2015-2022 (US$ Million, AGR %)
Figure 171 GSK plc: Regional Market Shares, 2022
Figure 172 INOVIO Pharmaceuticals: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 173 INOVIO Pharmaceuticals: R&D, 2015-2022 (US$ Million, AGR %)
Figure 174 Johnson & Johnson Services, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 175 Johnson & Johnson Services, Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 176 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
Figure 177 Merck Co., Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 178 Merck Co., Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 179 Merck Co., Inc.: Regional Market Shares, 2022
Figure 180 Moderna, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 181 Moderna, Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 182 Novavax: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 183 Novavax: R&D, 2015-2022 (US$ Million, AGR %)
Figure 184 Novavax: Regional Market Shares, 2022
Figure 185 Pfizer Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 186 Pfizer Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 187 Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 188 Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
Figure 189 Sanofi: Regional Market Shares, 2022
Figure 190 AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 191 AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
Figure 192 AstraZeneca: Regional Market Shares, 2022
Figure 193 SINOVAC: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 194 SINOVAC: R&D, 2015-2022 (US$ Million, AGR %)
Figure 195 Takeda Pharmaceutical Company Limited: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 196 Takeda Pharmaceutical Company Limited: R&D, 2015-2022 (US$ Million, AGR %)
Figure 197 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2022
Figure 198 Daiichi Sankyo, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 199 Daiichi Sankyo, Inc.: R&D, 2015-2022 (US$ Million, AGR %)

Companies Mentioned

AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL
Daiichi Sankyo, Inc.
Emergent BioSolutions Inc.
GSK plc
INOVIO Pharmaceuticals
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Moderna, Inc.
Novavax
Panacea Biotec
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
Sinopharm
SINOVAC
Takeda Pharmaceutical Company Limited
Aspen SA Operations (Pty) Ltd
Aurora Vaccines
Biocon Biologics Limited (BBL)
BioNTech
CureVac N.V.
DKSH Hong Kong
Dynavax Technologies Corporation
Frazier Healthcare Partners (Frazier)
Grand River Aseptic Manufacturing (GRAM)
Hilleman Laboratories
IDT Biologika
IEAYA Biosciences, Inc.
Medicago
Nykode Therapeutics
Ocugen, Inc.
Oragenics, Inc.
pHion Therapeutics
Precision NanoSystems
SK Bioscience
uniQure
Valneva SE
Vifor Pharma Ltd
Vir Biotechnology, Inc.
Zipline
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC)
Central Drugs Standard Control Organization (CDSCO)
Confederation of Indian Industry (CII)
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
European Commission (EC)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Global Alliance for Vaccines and Immunization (GAVI)
Indian Drug Manufacturer's Association (IDMA)
International Society of Pharmaceutical Engineering (IPSE)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Pan American Health Organization (PAHO)
Pharmaceutical and Medical Devices Agency (PMDA)
Public Health Agency of Canada (PHAC)
Therapeutic Goods Administration (TGA)
World Health Organization (WHO)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4916EUR$5,183USD£3,950GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€5600EUR$5,904USD£4,500GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6845EUR$7,216USD£5,500GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8650EUR$9,119USD£6,950GBP